Now showing items 1-3 of 3

    • Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work. 

      Robinson, M; James, J; Thomas, G; West, N; Jones, L; Lee, J; Oien, K; Freeman, A; Craig, C; Sloan, P; Elliot, P; Cheang, M; Rodriguez-Justo, M; Verrill, C; UK National Cancer Research Institute (NCRI) Cellular-Molecular Pathology (CM-Path) clinical trials working group (2019-04)
      While pathologists have always played a pivotal role in clinical trials ensuring accurate diagnosis and staging, pathology data from prognostic and predictive tests are increasingly being used to enrol, stratify and randomise ...
    • Training and accreditation standards for pathologists undertaking clinical trial work. 

      Rees, G; Salto-Tellez, M; Lee, JL; Oien, K; Verrill, C; Freeman, A; Mirabile, I; West, NP; National Cancer Research Institute (NCRI) Cellular-Molecular Pathology (CM-Path) clinical trials working group (2019-04)
      Clinical trials rely on multidisciplinary teams for successful delivery. Pathologists should be involved in clinical trial design from the outset to ensure that protocols are optimised to deliver maximum data collection ...
    • The use of digital pathology and image analysis in clinical trials. 

      Pell, R; Oien, K; Robinson, M; Pitman, H; Rajpoot, N; Rittscher, J; Snead, D; Verrill, C; UK National Cancer Research Institute (NCRI) Cellular-Molecular Pathology (CM-Path) quality assurance working group (2019-04)
      Digital pathology and image analysis potentially provide greater accuracy, reproducibility and standardisation of pathology-based trial entry criteria and endpoints, alongside extracting new insights from both existing and ...